The University of Wisconsin Carbone Cancer Center (UWCCC) Protocol Review and Monitoring System (PRMS) operates via one main committee, the Protocol Review and Monitoring Committee (PRMC), which functions as the Scientific Review Committee for alt cancer-related research protocols. The PRMC is charged with the scientific and resource review of all new and ongoing clinical and translational research protocols. In addition, the PRMC reviews all cancer-related clinical and translational research for compliance with the UW-Madison Conflict of Interest policies and assures an appropriate Data and Safety and Monitoring Plan is included in each proposal. The PRMC accomplishes this via the following responsibilities; ? Review of all new clinical and translational trials for scientific merit, priorities and resource allocation ? Prioritization of new clinical and translational trials relative to the clinical Disease Oriented Working Groups (DOWG)/Clinical Research Groups (CRG) ? Prioritization of research relative to the scope of UWCCC ? Review of all ongoing clinical and translational trials for scientific progress ? Closing studies for insufficient progress or due to prioritization changes Through established procedures the PRMC is the oversight mechanism through which all UW-Madison cancer-related clinical and translational research must flow, thus assuring that all research conducted at UWCCC is of the highest scientific merit and that UWCCC resources are used efficiently. The PRMS is supervised by the Associate Director for Clinical Research. The PRMC reports to UWCCC Clinical Research Committee, and is chaired by Dan Mulkerin, M.D., Associate Professor of Medicine, and co-chaired by Menggang Yu, Ph.D., Assistant Professor of Biostatistics and Medical Informatics. Dr. Mulkerin has over 15 years of clinical research performance and monitoring. Dr. Yu served as the biostatistics and clinical data management director for the Hoosier Oncology Group for four years prior to joining the University of Wisconsin faculty in January 2012.
The UWCCC Protocol Review and Monitoring System (PRMS) operates via one main committee, the Protocol Review and Monitoring Committee (PRMC), which functions as the Scientific Review Committee for all cancer-related research protocols. The PRMC is charged with the scientific and resource review of all new and ongoing clinical and translational research protocols. In addition, the PRMC reviews all cancer related clinical and translational research for compliance with the UW-Madison Conflict of Interest policies and assures an appropriate Data and Safety and Monitoring Plan is included in each proposal.
|Oberley, Christopher C; Bilger, Andrea; Drinkwater, Norman R (2015) Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis. Mol Carcinog 54:959-70|
|Wisinski, Kari B; Ledesma, Wendy M; Kolesar, Jill et al. (2015) A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1?,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract 21:416-24|
|Kolesar, Jill M; Pomplun, Marcia; Havighurst, Tom et al. (2015) Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. J Oncol Pharm Pract 21:128-31|
|Simoncic, Urban; Perlman, Scott; Liu, Glenn et al. (2015) Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer 13:e7-e17|
|Zhao, Z; Wang, L; Xu, W (2015) IL-13R?2 mediates PNR-induced migration and metastasis in ER?-negative breast cancer. Oncogene 34:1596-607|
|Chakravarty, Rubel; Hong, Hao; Cai, Weibo (2015) Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature. Curr Drug Targets 16:592-609|
|Wu, Jianqiang; Salva, Katrin A; Wood, Gary S (2015) c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death. J Invest Dermatol 135:861-8|
|LoConte, Noelle K; Razak, Albiruni R A; Ivy, Percy et al. (2015) A multicenter phase 1 study of ? -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs 33:169-76|
|Romens, Sarah E; McDonald, Jennifer; Svaren, John et al. (2015) Associations between early life stress and gene methylation in children. Child Dev 86:303-9|
|Ayvaci, Mehmet U S; Alagoz, Oguzhan; Chhatwal, Jagpreet et al. (2014) Predicting invasive breast cancer versus DCIS in different age groups. BMC Cancer 14:584|
Showing the most recent 10 out of 472 publications